United States Biotechnology & Medical Research

Genelux Corporation (GNLX)

Genelux Corporation experienced six insider trading transactions over the past ninety days, all involving sales by executives. These disposals totaled approximately 155,693 USD. This activity coincides with a 27.9% decline in stock value and a recent earnings report that missed expectations by 5%.
Ticker: GNLX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Genelux Corporation. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
244.57
Quantity 29,738 +45.8%
Value US$3,078,833
3.8
Yu Yong Chief Scientific Officer Officer
Transaction date
Sale
Price
342.04
Quantity 36,448 +33.3%
Value US$1,967,823
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
492.36
Quantity 59,290 -12.9%
Value US$4,375,754
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
2.74
Quantity 10,257 -3.1%
Value US$28,112
3.8
Yu Yong Chief Scientific Officer Officer
Transaction date
Sale
Price
2.75
Quantity 9,683 -3.6%
Value US$26,658
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
2.67
Quantity 34,463 -2.7%
Value US$91,899
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
2.95
Quantity 3,023 -0.2%
Value US$8,905
3.8
Yu Yong Chief Scientific Officer Officer
Transaction date
Sale
Price
2.94
Quantity 653 -0.2%
Value US$1,922
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
2.95
Quantity 653 -0.2%
Value US$1,924
3.5
Smither John W Non-Executive Director
Transaction date
Sale
Price
2.91
Quantity 12,000 -11.6%
Value US$34,898
3.5
JOHN SMITHER Director Non-Executive Director
Transaction date
Proposed sale
Price
2.91
Quantity 12,000
Value US$34,898
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.93
Quantity 192 -0.3%
Value US$563
3.1
Thomas John Non-Executive Director
Transaction date
Planned sale
Price
2.98
Quantity 10,000 -2.1%
Value US$29,801
3.1
JOHNNY THOMAS Officer Officer
Transaction date
Proposed sale
Price
3.05
Quantity 10,000
Value US$30,500
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.98
Quantity 270 -0.4%
Value US$804
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
2.94
Quantity 2,798 -0.5%
Value US$8,226
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
2.97
Quantity 605 -0.4%
Value US$1,799
3.8
Yu Yong Chief Scientific Officer Officer
Transaction date
Sale
Price
2.97
Quantity 605 -0.4%
Value US$1,798
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.51
Quantity 240 -0.4%
Value US$602
3.8
Yu Yong SVP, Clinical Development Officer
Transaction date
Sale
Price
2.42
Quantity 906 -0.6%
Value US$2,193
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
2.42
Quantity 906 -0.6%
Value US$2,193
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.42
Quantity 345 -0.5%
Value US$835
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
2.42
Quantity 3,582 -0.7%
Value US$8,668
3.1
Thomas John Non-Executive Director
Transaction date
Planned sale
Price
2.90
Quantity 10,000 -2.0%
Value US$28,957
3.1
JOHNNY THOMAS Officer Officer
Transaction date
Proposed sale
Price
2.98
Quantity 10,000
Value US$29,800
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
4.69
Quantity 165 -0.2%
Value US$774
3.1
Thomas John Non-Executive Director
Transaction date
Planned sale
Price
5.00
Quantity 10,000 -2.0%
Value US$50,008
3.1
JOHNNY THOMAS Director Non-Executive Director
Transaction date
Proposed sale
Price
5.56
Quantity 10,000
Value US$55,600
3.8
Yu Yong SVP, Clinical Development Officer
Transaction date
Sale
Price
5.37
Quantity 973 -0.7%
Value US$5,224
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Planned sale
Price
5.37
Quantity 4,509 -0.8%
Value US$24,211
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
5.37
Quantity 973 -0.6%
Value US$5,224
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
5.37
Quantity 343 -0.5%
Value US$1,842
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
3.36
Quantity 580 -0.8%
Value US$1,948
3.8
Yu Yong SVP, Clinical Development Officer
Transaction date
Sale
Price
3.36
Quantity 3,219 -2.1%
Value US$10,807
3.5
Zindrick Thomas President and CEO Officer
Transaction date
Planned sale
Price
3.33
Quantity 12,673 -2.3%
Value US$42,159
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
3.36
Quantity 1,463 -0.9%
Value US$4,912
3.5
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
3.33
Quantity 1,270 -0.8%
Value US$4,225
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
3.36
Quantity 1,244 -1.8%
Value US$4,177
3.5
Zindrick Thomas President and CEO Executive Director
Transaction date
Sale
Price
2.92
Quantity 10,764 -5.3%
Value US$31,431
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.92
Quantity 1,259 -3.5%
Value US$3,676
2.6
Ryder Sean General Counsel Officer
Transaction date
Sale
Price
2.92
Quantity 4,475 -8.6%
Value US$13,067
3.5
Cappello Joseph VP, Pharmaceutical Development Officer
Transaction date
Sale
Price
2.92
Quantity 4,737 -8.3%
Value US$13,832
3.8
Yu Yong VP, Clinical Trial Operations Officer
Transaction date
Sale
Price
2.92
Quantity 5,579 -10.5%
Value US$16,291
3.3
JAMES L TYREE Director Non-Executive Director
Transaction date
Proposed sale
Price
2.46
Quantity 3,460
Value US$8,512
3.3
Tyree James L Non-Executive Director
Transaction date
Sale
Price
2.46
Quantity 3,460 -7.0%
Value US$8,512
Zak Lourie S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
2.34
Quantity 2,103 -4.9%
Value US$4,921
3.4
Smalling Ralph Head of Regulatory Officer
Transaction date
Planned sale
Price
2.34
Quantity 2,510 -13.3%
Value US$5,873
3.5
Cappello Joseph VP, Pharmaceutical Development Officer
Transaction date
Sale
Price
2.34
Quantity 6,300 -30.1%
Value US$14,742
3.5
Zindrick Thomas President and CEO Executive Director
Transaction date
Planned sale
Price
2.34
Quantity 14,315 -27.7%
Value US$33,497
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.57
Quantity 33,080 -5.2%
Value US$84,946
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.73
Quantity 31,777 -4.8%
Value US$86,732
3.3
Tyree James L Non-Executive Director
Transaction date
Planned sale
Price
2.60
Quantity 1,730 -3.5%
Value US$4,499
3.3
JAMES L TYREE Director Non-Executive Director
Transaction date
Proposed sale
Price
2.51
Quantity 1,730
Value US$4,342
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.62
Quantity 31,376 -4.5%
Value US$82,227
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.51
Quantity 20,384 -2.8%
Value US$51,182
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.70
Quantity 23,383 -3.2%
Value US$63,200
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.09
Quantity 42,818 -5.5%
Value US$89,614
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.17
Quantity 142,589 -15.4%
Value US$309,846
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
1.98
Quantity 107,045 -10.4%
Value US$211,960
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.05
Quantity 15,918 -1.5%
Value US$32,605
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.11
Quantity 51,630 -4.7%
Value US$108,862
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.29
Quantity 40,000 -3.5%
Value US$91,416
SZALAY 2010 RETAINED ANNUITY TRUST 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
2.18
Quantity 400,000
Value US$872,000
3.8
Yu Yong VP, Clinical Trial Operations Officer
Transaction date
Sale
Price
2.12
Quantity 6,849 -38.7%
Value US$14,520
2.4
Jewett Caroline Head of Quality Officer
Transaction date
Sale
Price
2.12
Quantity 4,961 -23.5%
Value US$10,517
2.6
Ryder Sean General Counsel Officer
Transaction date
Planned sale
Price
2.12
Quantity 5,496 -22.1%
Value US$11,652
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.66
Quantity 17,094 -1.5%
Value US$62,624
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.58
Quantity 15,426 -1.3%
Value US$55,274
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.62
Quantity 3,446 -0.3%
Value US$12,478
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.82
Quantity 13,919 -1.2%
Value US$53,189
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.67
Quantity 6,025 -0.5%
Value US$22,111
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.30
Quantity 33,061 -2.7%
Value US$109,161
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.12
Quantity 20,535 -1.6%
Value US$63,981
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.25
Quantity 6,403 -0.5%
Value US$20,792
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-11-05 2026-11-03 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
29,738 +45.8%
244.57
US$3,078,833 		29,738 +45.8% 244.57 US$3,078,833
2026-11-05 2026-11-03 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
36,448 +33.3%
342.04
US$1,967,823 		36,448 +33.3% 342.04 US$1,967,823
2026-11-05 2026-11-03 S Sale
3.5
Zindrick Thomas

President and CEO

Officer
59,290 -12.9%
492.36
US$4,375,754 		59,290 -12.9% 492.36 US$4,375,754
2026-09-02 2026-08-31 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
10,257 -3.1%
2.74
US$28,112 		10,257 -3.1% 2.74 US$28,112
2026-09-02 2026-08-31 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
9,683 -3.6%
2.75
US$26,658 		9,683 -3.6% 2.75 US$26,658
2026-09-02 2026-08-31 S Sale
3.5
Zindrick Thomas

President and CEO

Officer
34,463 -2.7%
2.67
US$91,899 		34,463 -2.7% 2.67 US$91,899
2026-08-04 2026-08-04 S Sale
3.5
Zindrick Thomas

President and CEO

Officer
3,023 -0.2%
2.95
US$8,905 		3,023 -0.2% 2.95 US$8,905
2026-08-04 2026-08-04 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
653 -0.2%
2.94
US$1,922 		653 -0.2% 2.94 US$1,922
2026-08-04 2026-08-04 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
653 -0.2%
2.95
US$1,924 		653 -0.2% 2.95 US$1,924
2026-07-02 2026-07-01 S Sale
3.5
Smither John W
Non-Executive Director
12,000 -11.6%
2.91
US$34,898 		12,000 -11.6% 2.91 US$34,898
2026-07-01 2026-07-01 PrS Proposed sale
3.5
JOHN SMITHER

Director

Non-Executive Director
12,000
2.91
US$34,898 		12,000 2.91 US$34,898
2026-06-04 2026-06-03 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
192 -0.3%
2.93
US$563 		192 -0.3% 2.93 US$563
2026-06-02 2026-06-01 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.1%
2.98
US$29,801 		10,000 -2.1% 2.98 US$29,801
2026-06-01 2026-06-01 PrS Proposed sale
3.1
JOHNNY THOMAS

Officer

Officer
10,000
3.05
US$30,500 		10,000 3.05 US$30,500
2026-05-12 2026-05-11 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
270 -0.4%
2.98
US$804 		270 -0.4% 2.98 US$804
2026-05-12 2026-05-11 S Sale
3.5
Zindrick Thomas

President and CEO

Officer
2,798 -0.5%
2.94
US$8,226 		2,798 -0.5% 2.94 US$8,226
2026-05-12 2026-05-11 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
605 -0.4%
2.97
US$1,799 		605 -0.4% 2.97 US$1,799
2026-05-12 2026-05-11 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
605 -0.4%
2.97
US$1,798 		605 -0.4% 2.97 US$1,798
2026-03-26 2026-03-25 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
240 -0.4%
2.51
US$602 		240 -0.4% 2.51 US$602
2026-03-26 2026-03-24 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
906 -0.6%
2.42
US$2,193 		906 -0.6% 2.42 US$2,193
2026-03-26 2026-03-24 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
906 -0.6%
2.42
US$2,193 		906 -0.6% 2.42 US$2,193
2026-03-26 2026-03-24 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
345 -0.5%
2.42
US$835 		345 -0.5% 2.42 US$835
2026-03-26 2026-03-24 S Sale
3.5
Zindrick Thomas

President and CEO

Officer
3,582 -0.7%
2.42
US$8,668 		3,582 -0.7% 2.42 US$8,668
2026-03-03 2026-03-02 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.0%
2.90
US$28,957 		10,000 -2.0% 2.90 US$28,957
2026-03-02 2026-03-02 PrS Proposed sale
3.1
JOHNNY THOMAS

Officer

Officer
10,000
2.98
US$29,800 		10,000 2.98 US$29,800
2025-12-09 2025-12-05 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
165 -0.2%
4.69
US$774 		165 -0.2% 4.69 US$774
2025-12-02 2025-12-01 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.0%
5.00
US$50,008 		10,000 -2.0% 5.00 US$50,008
2025-12-01 2025-12-01 PrS Proposed sale
3.1
JOHNNY THOMAS

Director

Non-Executive Director
10,000
5.56
US$55,600 		10,000 5.56 US$55,600
2025-12-11 2025-11-17 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
973 -0.7%
5.37
US$5,224 		973 -0.7% 5.37 US$5,224
2025-12-11 2025-11-17 PlS Planned sale
3.5
Zindrick Thomas

President and CEO

Officer
4,509 -0.8%
5.37
US$24,211 		4,509 -0.8% 5.37 US$24,211
2025-12-11 2025-11-17 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
973 -0.6%
5.37
US$5,224 		973 -0.6% 5.37 US$5,224
2025-12-09 2025-11-17 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
343 -0.5%
5.37
US$1,842 		343 -0.5% 5.37 US$1,842
2025-12-09 2025-09-03 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
580 -0.8%
3.36
US$1,948 		580 -0.8% 3.36 US$1,948
2025-12-11 2025-08-21 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
3,219 -2.1%
3.36
US$10,807 		3,219 -2.1% 3.36 US$10,807
2025-12-11 2025-08-21 PlS Planned sale
3.5
Zindrick Thomas

President and CEO

Officer
12,673 -2.3%
3.33
US$42,159 		12,673 -2.3% 3.33 US$42,159
2025-12-11 2025-08-21 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
1,463 -0.9%
3.36
US$4,912 		1,463 -0.9% 3.36 US$4,912
2025-12-11 2025-08-21 S Sale
3.5
Cappello Joseph

Chief Technical Officer

Officer
1,270 -0.8%
3.33
US$4,225 		1,270 -0.8% 3.33 US$4,225
2025-12-09 2025-08-21 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
1,244 -1.8%
3.36
US$4,177 		1,244 -1.8% 3.36 US$4,177
2025-05-13 2025-05-12 S Sale
3.5
Zindrick Thomas

President and CEO

Executive Director
10,764 -5.3%
2.92
US$31,431 		10,764 -5.3% 2.92 US$31,431
2025-05-13 2025-05-12 S Sale
3.4
Smalling Ralph

Head of Regulatory

Officer
1,259 -3.5%
2.92
US$3,676 		1,259 -3.5% 2.92 US$3,676
2025-05-13 2025-05-12 S Sale
2.6
Ryder Sean

General Counsel

Officer
4,475 -8.6%
2.92
US$13,067 		4,475 -8.6% 2.92 US$13,067
2025-05-13 2025-05-12 S Sale
3.5
Cappello Joseph

VP, Pharmaceutical Development

Officer
4,737 -8.3%
2.92
US$13,832 		4,737 -8.3% 2.92 US$13,832
2025-05-13 2025-05-12 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
5,579 -10.5%
2.92
US$16,291 		5,579 -10.5% 2.92 US$16,291
2024-12-30 2024-12-30 PrS Proposed sale
3.3
JAMES L TYREE

Director

Non-Executive Director
3,460
2.46
US$8,512 		3,460 2.46 US$8,512
2024-12-30 2024-12-30 S Sale
3.3
Tyree James L
Non-Executive Director
3,460 -7.0%
2.46
US$8,512 		3,460 -7.0% 2.46 US$8,512
2024-12-18 2024-12-16 PlS Planned sale
Zak Lourie S.

Chief Financial Officer

Officer
2,103 -4.9%
2.34
US$4,921 		2,103 -4.9% 2.34 US$4,921
2024-12-18 2024-12-16 PlS Planned sale
3.4
Smalling Ralph

Head of Regulatory

Officer
2,510 -13.3%
2.34
US$5,873 		2,510 -13.3% 2.34 US$5,873
2024-12-18 2024-12-16 S Sale
3.5
Cappello Joseph

VP, Pharmaceutical Development

Officer
6,300 -30.1%
2.34
US$14,742 		6,300 -30.1% 2.34 US$14,742
2024-12-18 2024-12-16 PlS Planned sale
3.5
Zindrick Thomas

President and CEO

Executive Director
14,315 -27.7%
2.34
US$33,497 		14,315 -27.7% 2.34 US$33,497
2024-09-13 2024-09-13 S Sale
4.1
Szalay Aladar
Large shareholder
33,080 -5.2%
2.57
US$84,946 		33,080 -5.2% 2.57 US$84,946
2024-09-13 2024-09-12 S Sale
4.1
Szalay Aladar
Large shareholder
31,777 -4.8%
2.73
US$86,732 		31,777 -4.8% 2.73 US$86,732
2024-09-12 2024-09-11 PlS Planned sale
3.3
Tyree James L
Non-Executive Director
1,730 -3.5%
2.60
US$4,499 		1,730 -3.5% 2.60 US$4,499
2024-09-11 2024-09-11 PrS Proposed sale
3.3
JAMES L TYREE

Director

Non-Executive Director
1,730
2.51
US$4,342 		1,730 2.51 US$4,342
2024-09-11 2024-09-11 S Sale
4.1
Szalay Aladar
Large shareholder
31,376 -4.5%
2.62
US$82,227 		31,376 -4.5% 2.62 US$82,227
2024-09-11 2024-09-10 S Sale
4.1
Szalay Aladar
Large shareholder
20,384 -2.8%
2.51
US$51,182 		20,384 -2.8% 2.51 US$51,182
2024-09-11 2024-09-09 S Sale
4.1
Szalay Aladar
Large shareholder
23,383 -3.2%
2.70
US$63,200 		23,383 -3.2% 2.70 US$63,200
2024-09-06 2024-09-09 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
140,000
2.80
US$392,000 		140,000 2.80 US$392,000
2024-09-06 2024-09-03 S Sale
4.1
Szalay Aladar
Large shareholder
42,818 -5.5%
2.09
US$89,614 		42,818 -5.5% 2.09 US$89,614
2024-08-30 2024-08-30 S Sale
4.1
Szalay Aladar
Large shareholder
142,589 -15.4%
2.17
US$309,846 		142,589 -15.4% 2.17 US$309,846
2024-08-30 2024-08-29 S Sale
4.1
Szalay Aladar
Large shareholder
107,045 -10.4%
1.98
US$211,960 		107,045 -10.4% 1.98 US$211,960
2024-08-30 2024-08-28 S Sale
4.1
Szalay Aladar
Large shareholder
15,918 -1.5%
2.05
US$32,605 		15,918 -1.5% 2.05 US$32,605
2024-08-27 2024-08-27 S Sale
4.1
Szalay Aladar
Large shareholder
51,630 -4.7%
2.11
US$108,862 		51,630 -4.7% 2.11 US$108,862
2024-08-27 2024-08-23 S Sale
4.1
Szalay Aladar
Large shareholder
40,000 -3.5%
2.29
US$91,416 		40,000 -3.5% 2.29 US$91,416
2024-08-22 2024-08-23 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
400,000
2.18
US$872,000 		400,000 2.18 US$872,000
2024-07-08 2024-06-24 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
6,849 -38.7%
2.12
US$14,520 		6,849 -38.7% 2.12 US$14,520
2024-07-08 2024-06-24 S Sale
2.4
Jewett Caroline

Head of Quality

Officer
4,961 -23.5%
2.12
US$10,517 		4,961 -23.5% 2.12 US$10,517
2024-07-08 2024-06-24 PlS Planned sale
2.6
Ryder Sean

General Counsel

Officer
5,496 -22.1%
2.12
US$11,652 		5,496 -22.1% 2.12 US$11,652
2024-05-15 2024-05-15 S Sale
4.1
Szalay Aladar
Large shareholder
17,094 -1.5%
3.66
US$62,624 		17,094 -1.5% 3.66 US$62,624
2024-05-15 2024-05-14 S Sale
4.1
Szalay Aladar
Large shareholder
15,426 -1.3%
3.58
US$55,274 		15,426 -1.3% 3.58 US$55,274
2024-05-15 2024-05-13 S Sale
4.1
Szalay Aladar
Large shareholder
3,446 -0.3%
3.62
US$12,478 		3,446 -0.3% 3.62 US$12,478
2024-05-09 2024-05-08 S Sale
4.1
Szalay Aladar
Large shareholder
13,919 -1.2%
3.82
US$53,189 		13,919 -1.2% 3.82 US$53,189
2024-05-09 2024-05-07 S Sale
4.1
Szalay Aladar
Large shareholder
6,025 -0.5%
3.67
US$22,111 		6,025 -0.5% 3.67 US$22,111
2024-05-01 2024-05-01 S Sale
4.1
Szalay Aladar
Large shareholder
33,061 -2.7%
3.30
US$109,161 		33,061 -2.7% 3.30 US$109,161
2024-05-01 2024-04-30 S Sale
4.1
Szalay Aladar
Large shareholder
20,535 -1.6%
3.12
US$63,981 		20,535 -1.6% 3.12 US$63,981
2024-05-01 2024-04-29 S Sale
4.1
Szalay Aladar
Large shareholder
6,403 -0.5%
3.25
US$20,792 		6,403 -0.5% 3.25 US$20,792

See older Genelux Corporation insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Genelux Corporation history with Plus

Billed monthly · Cancel anytime

Explore more

More insider trading research around Genelux Corporation

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America